Pfizer
Pfizer
Seoul, South Korea8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis | Oligoarthritis, Juvenile, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, polyarticular juvenile idiopathic arthritis, rheumatic disorder | Recruiting | Not stated | 2026-08-03 | NCT05754710 | |
| Korean Post-marketing Surveillance for Xeljanz XR | Active Ankylosing Spondylitis; Active Moderate to Severe Rheumatoid Arthritis; Active Psoriatic Arthritis | Recruiting | Not stated | 2026-08-03 | NCT04876781 | |
| A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice. | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Not stated | 2026-05-18 | NCT07152119 | |
| Korea Comirnaty Post-marketing Surveillance | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-04-23 | NCT05032976 | |
| Post Marketing Surveillance(PMS) Study of Lorviqua in Korea | Metastatic ALK+ Non Small Cell Lung Cancer | Recruiting | Not stated | 2026-03-27 | NCT05599412 | |
| Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone | Pediatric Growth Hormone Deficiency | Active, not recruiting | Not stated | 2026-01-27 | NCT05509894 | |
| Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-01-14 | NCT06613984 | |
| Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not stated | 2025-11-24 | NCT06581848 |